BioPharmSignal logoBioPharmSignal

Biotech News

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics (AQST)Aquestive TherapeuticsEarnings

Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026 Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union, and the United Kingdom Completed AQST-108 phase 1 study in subjects with androgenic alopecia with

Related news

AQSTAquestive Therapeutics2026-05-06 11:00 EST

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

AQSTAquestive Therapeutics2026-07-29 11:00 EST

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

View all latest news

Aquestive Therapeutics

Oral Film Drug Delivery Company Aquestive Therapeutics develops medicines using proprietary film-based delivery technologies for allergic reactions and other conditions. Anaphylm Anaphylm is a postage-stamp-sized sublingual film containing a prodrug of epinephrine for severe allergic reactions, including anaphylaxis. It dissolves without...

Recent company news

AQSTAquestive Therapeutics2026-07-29 11:00 EST

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

AQSTAquestive Therapeutics2026-07-07 11:00 EST

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

AQSTAquestive Therapeutics2026-05-13 20:01 EST

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

AQSTAquestive Therapeutics2026-05-12 13:32 EST

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

AQSTAquestive Therapeutics2026-05-06 11:00 EST

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

Stock data

Close
3.92 USD
Market cap
493.02M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States